Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-965P is classified as a pseudogene of the U6 small nuclear RNA (snRNA) gene family, annotated as "RNA, U6 small nuclear 965, pseudogene"[2]. U6 snRNAs are essential parts of the spliceosome, participating directly in the splicing of pre-mRNA by facilitating RNA structural rearrangements within the spliceosome complex[1][3][5]. However, RNU6-965P lacks known protein-coding potential and is annotated as a pseudogene, meaning it is a genomic sequence similar to the parent U6 snRNA gene but generally considered transcriptionally inactive or non-functional in RNA splicing[2][4]. While some pseudogenes are known to produce regulatory noncoding RNAs that may have gene-regulatory or disease-modifying effects, there is no published evidence linking RNU6-965P to any specific biological function or disease[2][4]. It is not considered a therapeutic target, nor is it associated with any drugs, mechanisms of action, or biomarker roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 965, pseudogene (RNU6-965P).